Search results
Showing 1036 to 1050 of 2006 results for nice guidelines
Evidence-based recommendations on Memokath 051 Ureter stent for ureteric obstruction.
Evidence-based recommendations on futibatinib (Lytgobi) for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.
Show all sections
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel) and ustekinumab (Stelara) for plaque psoriasis in children and young people.
Discontinued Reference number: GID-CGWAVE0771
Evidence-based recommendations on dapagliflozin (Forxiga) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.
Reducing the mortality and morbidity for healthcare associated infections
Discontinued Reference number: GID-NG10059
Discontinued Reference number: GID-NG10163
In development Reference number: GID-QS10113 Expected publication date: TBC
NICE has developed a medtech innovation briefing (MIB) on microINR for anticoagulation therapy .
MMprofiler for prognostic risk classification in multiple myeloma (MIB270)
NICE has developed a medtech innovation briefing (MIB) on MMprofiler for prognostic risk classification in multiple myeloma .
Discontinued Reference number: GID-NG10053
Discontinued Reference number: GID-NG10168
Discontinued Reference number: GID-NG10167
FebriDx for C-reactive protein and myxovirus resistance protein A testing (MIB224)
NICE has developed a medtech innovation briefing (MIB) on FebriDx for C-reactive protein and myxovirus resistance protein A testing .
NICE has developed a medtech innovation briefing (MIB) on RT300 for spinal cord injury rehabilitation .